UEDA Takanori

FacultyPresident / Vice-president
Teacher OrganizationPresident / Vice-president
Education and
 Research Organization
President / Vice-president
PositionPresident
Last Updated: 19/07/23 18:50

Researcher Profile & Settings

Name

    UEDA Takanori

Affiliation

  •  President / Vice-president President
  •  President / Vice-president Trustee, Vice President for Planning and Strategy
  •  Research Center for Child Mental Development
  •  Graduate School of Medical Sciences

Education

  • 1983Kyoto University 内科学
  • 1974Kyoto University

Academic & Professional Experience

  • Jul. 1984Jul. 1986Visting Scholar,University of North Caroline at Chapel Hill,USA

Research Activities

Published Papers

  • A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Past-remission Therapy for Acute Myeloid Leukemia
    T.Fukushima, Y.Urasaki, M.Yamaguchi, M.Ueda, K.Morinaga, T.Haba, T.Sugiyama, S.Nakao, H.Origasa, H.Umihara, T.Ueda
    Anticancer Res 32(2) 643-648 Apr.  2012 Refereed
  • Clinical utility of the neutrophil distributin pattern obtained using the CELL-DYN SAPPHIRE hematology analyzer for the diagnosis of myelodysplastic syndrome
    T.Inaba, Y.Yuki, S.Yuasa, N.Fujita, K.Yoshitomi, T.Kamisako, K.Torii, T.Okada, Y.Urasaki, T.Ueda, K.Tohyama
    Int J Hematol 94 169-177 Jul.  2011 Refereed
  • Inhibition of nucleotide excision repair by fludarabine in normal lymphocytes in vitro, measured by the alkaline single cell gel electrophoresis (Comet) assay
    T.Ueda
     93 567-573 2002
  • Reversible defect of123 Ⅰ-15-(p-iodophenyl)-9-(R,S)-methylpentadecanoic acid indicates residual viability within infarct-related area
    T.Ueda
     16(3) 183-187 2002
  • Dexamethasone-resistant human pre-B leukemia 697 cell line evolving elevation of intracellular glutathione level: An additional resistant mechanism
    T.Ueda
     93 582-590 2002
  • High molecular weight DNA fragmentation assay: A sensitive method for monitoring in vivo response to antileukemic chemotherapy
    T.Ueda
     22 3025-3028 2002
  • Expression of the antiapoptotic gene survivin in chronic myeloid leukemia
    T.Ueda
     22 inpress 2002
  • Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis
    T.Ueda
     93 849-856 2002
  • Alkylator-induced DNA excision repair in human leukemia CCRF-CEM cells in vitro, measured using the single-cell gel electrophoresis (comet) assay
    T.Ueda
     76 328-332 2002
  • Doxycycline induces apoptosis by way of caspase-3 activation with inhibition of matrix metalloproteinase in human T-lymphoblastic leukemia CCRF-CEM cells
    T.Ueda
     140(6) 382-386 2002
  • Evaluation of arteriolar hyalinosis of skin in patients with chronic congestive heart failure
    T.Ueda
     66(4) 382-384 2002
  • Serum cytokine level during continuous venovenous hemofiltration in toxic shock-like syndrome due to group G streptococcus bacteremia in a patient with idiopathic thrombocytopenic purpura
    T.Ueda
     34(6) 403-406 2002
  • 1-beta-D-arabinofuranosylcytosine is cytotoxic in quiescent normal lymphocytes undergoing DNA excision repair
    T.Ueda
     93 1334-1341 2002
  • An autopsy case of desseminated mucormycosis in a neutropenic receiving chemotherapy for the underlying solid malignancy
    T.Ueda
     8 103-105 2002
  • Pure red cell aplasia developed into myeloproliferation with myelodysplasia and subsequent leukemia after cyclosporin A therapy
    T.Ueda
     75 514-518 2002
  • Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells. (共著)
    T.Ueda
     61:172-177 2001
  • Time sequential expression of markers of apoptosis induced by 1-βD-arabinofuranosylcytosine in human T-lymphoblastic leukemia CCRF-CEM cells. (共著)
    T.Ueda
     21: 1987-1996 2001
  • Monitoring of intracellular 1-β-D-arabinofuranosylcytosine 5’-triphosphate in 1-β-D-arabinofuranosylcytosine therapy at low and conventional doses. (共著)
    T.Ueda
     92: 546-553 2001
  • Close correlation of 1-β- D-arabinofuranosylcytosine 5’-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N4-behenoyl-1-β-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia. (共著)
    T.Ueda
     92: 975-982 2001
  • Long-term follow-up of the clinical efficacy of chemotherapy for acute myeloid leukemia at a single institute
    T.Ueda
     7: 156-162 2001
  • A harmacokinetic study of idarubicin in japanese patients with malignant lymphoma: Relationship
    T.Ueda
     74: 297-302 2001
  • Successful lamivudine therapy for post-chemotherapeutic fluminant hepatitis B in a hepatitis B virus carrier with non-Hodgkin's lymphoma: case report and review of the literature. (共著)
    T.Ueda
     80 (8): 483-484 2001
  • Successful treatment of Aspergillus spondylodiscitis with high-dose itraconazole in a patient with acute myelogenous leukemia.(共著)
    T.Ueda
     15(10): 1670-1671 2001
  • Acute fatty liver of pregnancy compliacted with anterior pituitary insuffciency
    T.Ueda
     40: 1227-1231 2001
  • Fulminant Japanese Spotted Fever Associated with Hypercytokinemia
    T.Ueda
     39(6): 2341-2343 2001
  • Successful Salvage Treatment of Recurrent Malignant Lymphoma with Irinotecan(CPT-11): pharmacokinetics.(共著)
    T.Ueda
     3: 8-9 2001
  • Nitric oxide synthase activity in peripheral polymorphonuclear leukocytes in patients with chronic congestive heart failure.(共著)
    T.Ueda
     87: 183-187 2001
  • Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled uncleotide-excision repair. (共著)
    T.Ueda
     7(8): 961-966 2001
  • Clinical significance of reverse redistribution on resting Thallium-201 imaging in patients with vasospastic angina. (共著)
    T.Ueda
     15(1): 65-68 2001
  • Primary Extranodal Malignant Lymphoma
    T.Ueda
     58(3), 673-676 2000
  • Evidence Based Clinical Approach for Acute Lymphoblastic
    T.Ueda
     3(), 599-607 2000
  • DNA Interacting Drugs
    T.Ueda
     8(2), 136-142 2000
  • Deep Seated Fungal Infection
    T.Ueda
     49(増刊), 1384-1387 2000
  • Differentiation Induction in Non-lymphocytic Leukemia Cells Upon Treatment with Mycophenolate Mofetil
    T.Ueda
     24(), 761-768 2000
  • Effent of PSC833 on the Cytotoxicity and Pharmacodynamics of Mitoxantrone in Multidrug-resistant
    T.Ueda
     24(), 249-254 2000
  • Surveillance of the Serum Candida Antigen Titer for Initiation of Antifungal Therapy After Postremission Chemotherapy in Patients with Acute Leukemia
    T.Ueda
     71(), 266-272 2000
  • Interleukin-6 Reduces Serum Urate Level
    T.Ueda
     27(2), 554 2000
  • Latent Overproductive Hyperuricemia Increases in Patients During the Intermittent Phase of Gouty Arthritis Under Long-term Antihyperuricemic Treatment
    T.Ueda
     10(), 207-210 2000
  • The Role of Protein-tyrosine Phosphorylation and Gelatinase Production in the Migration and Proliferation of Smooth Muscle Cells
    T.Ueda
     149(), 51-59 2000
  • Clinical Significance of Augmented Fluorine-18 Deoxyglucose Uptake in Remote Normpoerfused Myocardium in Patients with Acute Coronary Syndrome Under Fasting Conditions
    T.Ueda
     7(5), 454-460 2000
  • Cytokine Modulation Induced by Minocycline in Tsutsugamushi Disease
    T.Ueda
     74(7), 598-600 2000
  • Reduction of Serum Uric Acid in Patients Receiving Recombinant Human Interleukin-6
    T.Ueda
     24(2), 180-185 2000
  • Torsade de Pointes Associated with Hypokalemia after Anthracycline Treatment in a Patient with Acute Lymphocytic Leukemia
    T.Ueda
     171(), 172-179 2000
  • Anhidrosis During Long-term Hydroxyurea Therapy in a Patient with Chronic Myelogenous Leukemia
    T.Ueda
     41(11), 1214-1219 2000
  • Drugs which after Nucleotide Metabolism
    T.Ueda
     8(2), 131-135 2000
  • Cutaneous T-cell lymphoma : Mycosis fungoides/S(]E85EE[)zary syndrome
    T.Ueda
     188(10) 937-941 1999
  • Anemia of chronic disorders
    T.Ueda
     87(8) 1389-1393 1999
  • Peripheral Blood Stem Cell Collection and Transplantation using the Haemonetics Multi Component System
    T.Ueda
     20(1) 21-27 1999
  • A novel Philadelphia chromosome-positive cell line with multipotential properties
    T.Ueda
     69(4) 256-259 1999
  • Evalution of cell-killing effects of 1-β-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation sytstem
    T.Ueda
     59(11) 2629-2637 1999
  • Effect of PSC833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells
    T.Ueda
     23(1) 37-42 1999
  • Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSGAML-89 consolidation therapy
    T.Ueda
     70(1) 56-57 1999
  • Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line
    T.Ueda
     19(6) 5111-5116 1999
  • Molecular remission induced by fractionated dose-escalating donor leukocyte infusion without graft-versus-host disease in a patient with chronic myelogenous leukemia relapsed after allogeneic bone marrow transplantation
    T.Ueda
     19(6) 5631-5634 1999
  • Urate transport in nephrons of gouty patients : quantitative analysis of urate transport in nephrons
    T.Ueda
     3 169-174 1999
  • Influence of treated blood pressure on progression of silent cerebral infarction
    T.Ueda
     17(5) 679-685 1999
  • Reciprocal ST-segment depression associated with exercise-induced ST-segment elevation indicates residual viability after myocardial infarction
    T.Ueda
     33(3) 620-626 1999
  • HLA antigens in patients with variant angina in Japan
    T.Ueda
     70(2) 249-252 1999
  • Increased nitric oxide synthase activity in peripheral polymorphonuclear cells in chronic heart failure patients
    T.Ueda
     46 99-101 1999
  • Successuful treatment of cytomegalovirus retinities in a patient with malignant lymphoma : a case report and review of the literature
    T.Ueda
     69 256-259 1999
  • Hepatic tumor ruputure following effectual treatment with irinotecan in a patient with highly refractory malignant lymphoma
    T.Ueda
     70 178-180 1999
  • Successful salvage treatment with irinotecan (CPT-11) of recurrent malignant lymphoma in anaged patient ; and CPT-11 pharmacokinetics
    T.Ueda
     69(3) 165-169 1999
  • Successful treatment of acquired myelofibrosis with pure red cell aplasia by cyclosporine
    T.Ueda
     104 422-424 1999
  • A case of renal insufficiency and hyperuricemia with allopurinol induced pancytopenia
    T.Ueda
     23(1) 17-22 1999
  • Evaluation of the knee joints with CT in gouty patients
    T.Ueda
     29(1) 133-134 1999
  • Case of chronic renal failure with sudden progression of renal dysfunction due to furosemide hypersensitivity
    T.Ueda
     88(1) 130-132 1999
  • Secondary hyperuricemia : Anticancer agents
    T.Ueda
     6(2) 108-113 1998
  • The expression of co-stimulatory molecules and their relationship to the prognosis of human acute myeloid leukaemia : poor prognosis of B7-2-positive leukaemia
    T.Ueda
    (102) 1257-1262 1998
  • Idarubicin and idarubicinol are less affected by topoisomerase (]G0002[)-related multidrug resistance than is daunorubicin
    T.Ueda
    (22) 625-629 1998
  • Differentiation and reduction of intracellular GTP levels in HL-60 and U937 cells upon treatment with IMP dehydrogenase inhibitors
    T.Ueda
    (431) 549-553 1998
  • Low intracellular GTP level does not induce cell differentiation in PKC-β-defficient human myeloid leukemia cells
    T.Ueda
    (431) 429-432 1998
  • Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy : the ALL90 study of the Japan Adult Leukemia Study Group
    T.Ueda
     68(3) 279-289 1998
  • International Forum : Japan-Report on informed consent in blood transfusions
    T.Ueda
     19(3) 201-215 1998
  • Echocardiographic and hematological variables as a risk factor for stroke in chronic nonvalvular atrial fibrillation
    T.Ueda
     32(1) 15-20 1998
  • Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia. The ALL-87 Study of the Japan Adult Leukemia Study Group (JALSG)
    T.Ueda
    (68) 421-429 1998
  • Comparison of intracellular GTP levels during differentiation induction upon treatment with IMP dehydrogenate inhibitors or all-trans retinoic acid
    T.Ueda
     22(2) 125-132 1998
  • Clinical Pharmacology of Intermediate and Low-dose cytosine arabinoside (ara-C) Therapy in Patients with Hematologic Malignancies. Purine and Pyrimidine metabolism in man (]G0009[)
    T.Ueda
     647-651 1998
  • Mechanism of action of anticancer agents that affect nucleic acid metabolism in tumor cells
    T.Ueda
     44(2) 125-128 1998
  • Current situation and perspective for treatment of acute myelogenous leukemia in adults
    T.Ueda
     25(3) 295-302 1998
  • Fever : leukemia and malignant lymphoma
    T.Ueda
     47(9) 2536-2540 1998
  • Primary cardiac B-cell lymphoma
    T.Ueda
     97(2) 220-221 1998
  • Early manifestation of septic shock and disseminated intravascular coagulation complicated by acute myocardial infarction in a patient suspected of having legionnaires' disease
    T.Ueda
    (72) 286-292 1998
  • Molecular analysis of a case of philadelphia chromosome-positive acute myeloid leukemia
    T.Ueda
     17(1B) 625-628 1997
  • Recent progress in the therapy of MDS
    T.Ueda
     135 361-373 1997
  • Apoptosis of acute myeloblastic leukemia cells induced by combination of anti-leukemic agents(Ara-C, VP-16), G-CSF and CD95/Fas stimulation
    T.Ueda
     11(3) 272-274 1997
  • Improvement of bleeding tendency and normalized platelet count increment following splenctomy in a patient with refractory anemia
    T.Ueda
     38(6) 532-538 1997
  • Anti-leukemia chemotherapy of high-risk myelodysplastic syndromes
    T.Ueda
     2 160-163 1997
  • Differentiation induction in non-lymphocytic leukemia cells upon treatment with mizoribine
    T.Ueda
     66(3) 335-344 1997
  • Increased levels of macrophage colony-stimulating factor, gamma interferon, and tumor necrosis factor alpha in sera of patients with Orientia tsutsugamushi infection
    T.Ueda
     35(12) 3230-3322 1997
  • Gout and hyperuricemia in patients with hematologic disorder and malignancy
    T.Ueda
     5(1) 14-20 1997
  • Disturbed autonomic activity precedes ischemic episodes in patients with variant angina
    T.Ueda
     2(4) 313-318 1997
  • Recovery of perfusion, glucose utilization and fatty acid utilization in stunned myocardium
    T.Ueda
     38(12) 1835-1837 1997
  • Susceptibillity to infection due to diminished interferon- α -producing capacity in patients with refractory anemia with excess of blasts or refractory anemia with excess of blasts in transformation
    T.Ueda
     2 131-138 1997
  • The pharmacokinetic study in the two case reports with elevated trough levels of cyclosporine on whole blood after allogeneic bone marrow transplantation
    T.Ueda
     14(4) 288-295 1997
  • A new sensitive method for determination of intracellular 1-β-D-arabinofuranosylcytosine 5'-triphosphate content in human materials in vivo
    T.Ueda
     56 1800-1804 1996
  • Superior cytotoxic potency of mitoxantrone in interaction with DNA : Comparison with that of daunorubicin
    T.Ueda
     8(2) 95-100 1996
  • Establishment of a daunorubicin-resistant cell line which shows multi-drug resistance by multifactorial mechanisms
    T.Ueda
     16 709-714 1996
  • Role of serine and ICE-like proteases in induction of apoptosis by etoposide in human leukemia HL-60 cells
    T.Ueda
     10 821-824 1996
  • Recent developments with novel anthracyclines for the treatment of haematological malignancies
    T.Ueda
     5(12) 1639-1646 1996
  • Cardiac energy metabolism at several stages of adriamycin-induced heart failure in rats
    T.Ueda
     55 217-225 1996
  • Relation between severity of magnesium deficiency and frequency of anginal attacks in men with variant angina
    T.Ueda
     28(4) 897-902 1996
  • Long-term oral L-carnitine treatment prolongs the survival in rats with adriamycin-induced heart failure
    T.Ueda
     2(4) 293-299 1996
  • All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia
    T.Ueda
     85(5) 1202-1206 1995
  • A novel factor-dependent human myelodysplastic cell line,MDS92.contains haemopoietic cells of several lineages
    T.Ueda
     91 795-799 1995
  • Recent progress in chemotherapy of leukemia
    T.Ueda
     34(4) 285-288 1995
  • Quantitative description of morphologic changes effected by antileukemic a gents in L1210 leukemia cells
    T.Ueda
     15(1) 133-140 1995
  • Enhancement of Ca2+-dependent Endonuclease activity in L1210 cells during apoptosis induced by 1-β-D-arabinofuranosylcytosine : Possible involvement of activating factor(s)
    T.Ueda
     86(7) 677-684 1995
  • Clinical pharmacology of 1- β -D- arabinofuranosylcytosine-5' -stearylphosphate, an orally administered long-acting derivative of low-dose 1- β -D-arabinofuranosylcytosine
    T.Ueda
     54(1) 109-113 1994
  • A Double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia
    T.Ueda
     83(8) 2086-2092 1994
  • Circumvention of daunorubicin resistance by a new tamoxifen derivative, toremifene, in multidrug-resistant cell line
    T.Ueda
    (85) 659-664 1994
  • Altered responses of purified blast cells from the myelodysplastic syndromes to colony-stimulating factors in vitro : comparison with normal blast cells
    T.Ueda
    (22) 539-545 1994
  • Pharmacokinetic and clinical pilot study of high-dose intermittent ubenimex treatment in patients with myelodysplastic syndrome
    T.Ueda
    (14) 2093-2098 1994
  • Influence of idarubicinol on the antileukemic effect of idarubicin
    T.Ueda
     18(12) 943-947 1994
  • Establishment and characterization of a novel myeloid cell line from the bone marrow of a patient with the myelodysplastic syndrome
    T.Ueda
    (87) 235-242 1994
  • Differential expression of interleukin-2 receptors ( α and β chain)in mature lymphoid neoplasms
    T.Ueda
    (46) 179-183 1994
  • Modulation of the effect of 1- β -D-arabinofuranosylcytosine by 6-mercaptopurine in L1210 cells
    T.Ueda
    (85) 978-985 1994
  • Induction of cell differentiation by IMPDH anitisense olignomer in HL-60 and k562 human leukemic cell lines
    T.Ueda
     370 757-760 1994
  • Sequential promotion of normal and leukemic hemopoiesis by recombinant human granulocyte colony-stimulating factor during the course of myelodysplastic syndrome
    T.Ueda
     59(1) 47-52 1993
  • Evaluation of oral aclarubicin treatment for tumors of the gastrointestinal tract
    T.Ueda
     13,909-914 1993
  • A randomized controlled study of granulocyte colony stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia
    T.Ueda
     58,73-81 1993
  • Role of calcium ion in induction of apoptosis by etoposide in human leukemia HL-60 cells
    T.Ueda
     196(2) 927-934 1993
  • DNA damage and cell killing by camptothecin and its derivative in human leukemia HL-60 cells
    T.Ueda
     84,566-573 1993
  • Action mechanism of idarubicin(4-demethoxydaunorubicin)as compared with daunorubicin in leukemic cells
    T.Ueda
     57,121-130 1993
  • Enhancement of cytosine arabinoside cytotoxicity by granulocyte/macrophage colony-stimulating factor and granulocyte colony-stimulating factor in a human myeloblastic leukemia cell line
    T.Ueda
     84,445-450 1993
  • Discordant LFA-1/ICAM-1 expression in a case of secondary plasma cell leukemia associated with subcutaneous plasmacytoma
    T.Ueda
     42,299-304 1993
  • Basis and Clinics of Multidrug Resistance(MDR)-Antineoplastic agent and MDR
    T.Ueda
     27(1) 15-24 1993
  • Recent Progress in Acute Myelogenous Leukemia-Recent progress in chemotherapy of acute myelogenous leukemia
    T.Ueda
     27(3) 196-206 1993
  • Prophylactic use of ofloxacin in granulocytopenic patients with hematological malignancie during post-remission chemotherapy
    T.Ueda
     31(3) 319-324 1992
  • Morphologic difference in leukemic cells(L1210) exposed to 1-β-D-arabinofuranosylcytosine and daunorubicin
    T.Ueda
     12,941-948 1992
  • Phenotypical characteristics of acute myelocytic leukemia associated with the t(8 : 21)(q22. q22)chromosomal abnormality
    T.Ueda
     80(2) 470-477 1992
  • Biological significance of multiple cytokines produced by acute myeloblastic leukemia cells
    T.Ueda
     10,125-133 1992
  • Pharmacokinetics and intracellular metabolism of ara-C and its derivatives
    T.Ueda
     23(1) 365-369 1992
  • Clinical application of enzyme inhibitors -hematologic malignancies
    T.Ueda
     49 1991
  • Atypical lymphocytes with a multilobated nucleus from a patient with Tsutsugamushi Disease (Scrub Typhus) in Japan
    T.Ueda
     36,150-151 1991
  • Pharmacological studies of retinol palmitate and its clinical effect in patients with acute non-lymphocytic leukemia
    T.Ueda
     15(6) 463-471 1991
  • Intensive therapy of serious and intractable infection-intractable infection in patients with hematologic malignancies
    T.Ueda
     7(3) 484-491 1991
  • Metabolism of ara-C and its related compounds
    T.Ueda
     15(2) 103-108 1991
  • Successful treatment of myelodysplastic syndrome with 1-β-D-arabinofuranosylcytosine 5'-stearylphosphate
    T.Ueda
     14(42320) 1990
  • Reduction of leukemia cell growth in a patient with acute promyelocytic leukemia treated by retinol palmitate
    T.Ueda
     14(7) 595-600 1990
  • Clinical pharmacology of N4-palmitoyl-1-β-D-arabinofuranosylcytosine in patients with hematologic malignancies
    T.Ueda
     24(6) 1989
  • Diagnosis and treatment of special disorders-eosinophilic leukemia
    T.Ueda
     21,497-501 1989
  • Pharmacokinetics of stearyl-ara-CMP(YNK-01)in patients with hematologic neoplasm
    T.Ueda
     16(9) 3303-3306 1989
  • Serious and intractable infection-Hematology
    T.Ueda
     4(1) 13-18 1988
  • Infections in the field of internal medicine-chemotherapy of sepsis
    T.Ueda
     6(6) 14-18 1988
  • Folate analogues as inhibitors of thymidylate synthase
    T.Ueda
     30(4) 1987
  • Inhibitory action of 10-deazaaminopterins and their polyglutamates on human thymidylate synthase
    T.Ueda
     30 1986
  • Acute leukemia with two cell populations of lymphoblasts and monoblasts
    T.Ueda
     8(1) 1984
  • Clinical pharmacology of antileukemic antimetabolites
    T.Ueda
     33(7) 1319-1324 1984
  • Pharmacokinetics of N4-behenoyl-1-β-D-arabinofuranosylcytosine in patients with acute leukemia
    T.Ueda
     43 1983
  • Intracellular distribution of N4-behenoyl-1-β-D-arabinofuranosylcytosine in blood cells
    T.Ueda
     74 1983
  • O-03 発熱性好中球減少症に対する抗真菌薬の有効性(深在性真菌症,一般演題(口演),医真菌学の新たな地平へ)
     56(1) Sep.  2015
  • The first case of familial Lesch-Nyhan variant in Japan revealed by molecular genetic examination
    Matsuda Yasufumi;Yamada Yasukazu;Wakamatsu Nobuaki;Misawa Miwa;Egawa Katsuya;Yamauchi Takahiro;Nakamura Makiko;Hasegawa Hiroshi;Ichida Kimiyoshi;Ueda Takanori
    Uric acid research 39(2) 121-128 2015 Refereed
    Lesch-Nyhan disease is sex-linked recessive disorder of children occurring at a very young age and a rare condition that results in severe hyperuricemia, motor disability, developmental delay, and self-injurious behavior. These conditions are attributed to congenital deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT), and individuals with less severe problems are called Lesch-Nyhan variants (LNV). We diagnosed a young man who had hyperuricemia and gout, and his two brothers who also had hyperuricemia as LNV. Molecular analysis of the three brothers clarified a point mutation of c.59A>T (p.D20V) in their HPRT gene (HPRT1) and their enzymatic activities were under the detection limits. Their mother was heterozygous for the mutant HPRT1. Regarding point mutations of HPRT1 in LNV, 120 cases have been reported. The point mutation of c.59A>T had already been reported in 1991 in The United States, but it was only a single case. We have detected the mutation in one family, and this is the first report from Japan.
  • 腫瘍崩壊症候群とラスブリカーゼの適応
    Morita Mihoko;Yamauchi Takahiro;Ueda Takanori
    Uric acid research 39(2) 2015
  • 健診受診者における高尿酸血症と脂質異常症についての検討
    Oiwa Kana;Shigemi Hiroko;Morita Mihoko;Matsuda Yasufumi;Ueda Takanori;Yamauchi Takahiro
    GOUT AND NUCLEIC ACID METABOLISM 40(1) Jul.  2016 Not refereed
  • 健診センターの職員における尿酸値異常症とメタボリックシンドロームとの相関についての解析
    Shigemi Hiroko;Oiwa Kana;Morita Mihoko;Matsuda Yasufumi;Ueda Takanori;Yamauchi Takahiro
    GOUT AND NUCLEIC ACID METABOLISM 40(1) 60-60 Jul.  2016 Not refereed
  • Hyperuricemia in association with hematological diseases
    Yamauchi Takahiro;Ueda Takanori
    Nippon Rinsho Hyperuricemia and Hypouricemia 74(増刊号9) 125-135 Nov.  2016 Not refereed
  • Urinalysis(urinary excretion of uric acid, uric acid clearance, creatinine clearance)
    Yamauchi Takahiro;Morita Mihoko;Ueda Takanori
    Nippon Rinsho Hyperuricemia and Hypouricemia 74(増刊号9) 171-176 Nov.  2016 Not refereed
  • Therapeutic goal of hyperuricemia
    Ueda Takanori
    Nippon Rinsho Hyperuricemia and Hypouricemia 74(増刊号9) 199-203 Nov.  2016 Not refereed
  • Tumor lysis syndrome
    Yamauchi Takahiro;Ueda Takanori
    Nippon Rinsho Hyperuricemia and Hypouricemia 74(増刊号9) 323-326 Nov.  2016 Not refereed
  • Secondary hypouricemia in patients with malignancies
    Inai Kunihiro; Ueda Takanori
    Nippon Rinsho Hyperuricemia and Hypouricemia 74(増刊号9) 405-412 Nov.  2016 Not refereed
  • High Risk of Tumor Lysis Syndrome in Symptomatic Patients with Multiple Myeloma with Renal Dysfunction Treated with Bortezomib.
    Oiwa Kana;Morita Mihoko;Kishi Shinji;Okura Miyuki;Tasaki Toshiki;Matsuda Yasufumi;Tai Katsunori;Hosono Naoko;Ueda Takanori;Yamauchi Takahiro
    Anticancer research 36(12) Dec.  2016 Not refereed
    BACKGROUND/AIM:Tumor lysis syndrome (TLS) is a life-threatening complication associated with cancer chemotherapy. We retrospectively evaluated the risk of developing TLS in patients with symptomatic multiple myeloma undergoing chemotherapy.;PATIENTS AND METHODS:Sixty-four patients (median age=71 years, range=48-87 years, 35 males/29 females) who were treated at our Institution between April 2006 and December 2015 were evaluated.;RESULTS:A total of 124 chemotherapy courses were administered, of which 63 courses were bortezomib-based regimens and 34 courses were immunomodulatory drug (IMiD)-based regimens. TLS occurred in 13 (10.5%) out of 124 chemotherapy courses with five (4.0%) cases of laboratory TLS and eight (6.5%) cases of clinical TLS. The incidences of TLS were 17.5% for bortezomib-containing regimens and 3.2% for non-bortezomib-based regimens. No TLS occurred in the patients treated with IMiD-containing regimens. TLS occurred more frequently in the patients with elevated uric acid, creatinine, or beta-2-microglobulin levels at baseline. The patients with disease classified as advanced International Staging System also developed TLS more frequently. All the patients who developed clinical TLS received bortezomib-containing regimens (8/63, 12.7%). Among them, patients with elevated values of uric acid or creatinine developed clinical TLS more often than those without such elevation. The incidence of clinical TLS was 33.3% if the patients had renal dysfunction at baseline and were subsequently treated with bortezomib-based regimens (8/24 cases).;CONCLUSION:Patients with renal dysfunction or a high uric acid level receiving bortezomib-based chemotherapy have a high risk of developing TLS.
  • Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
    Matsuda Yasufumi;Yamauchi Takahiro;Hosono Naoko;Uzui Kanako;Negoro Eiju;Morinaga Koji;Nishi Rie;Yoshida Akira;Kimura Shinya;Maekawa Taira;Ueda Takanori
    Cancer science 107(7) Jun.  2016 Refereed
    :The major mechanism of imatinib (IM) resistance of CML is the reactivation of ABL kinase either through BCR-ABL gene amplification or mutation. We investigated the cytotoxicity of a pan-ABL tyrosine kinase inhibitor, ponatinib, and a pan-histone deacetylase inhibitor, panobinostat, against IM-resistant CML cells inツꀀvitro. Two different IM-resistant cell lines, K562/IM-R1 and Ba/F3/T315I were evaluated in comparison with their respective, parental cell lines, K562 and Ba/F3. K562/IM-R1 overexpressed BCR-ABL due to gene amplification. Ba/F3/T315I was transfected with a BCR-ABL gene encoding T315I-mutated BCR-ABL. Ponatinib inhibited the growth of both K562/IM-R1 and Ba/F3/T315I as potently as it inhibited their parental cells with an IC50 of 2-30ツꀀnM. Panobinostat also similarly inhibited the growth of all of the cell lines with an IC50 of 40-51ツꀀnM. This was accompanied by reduced histone deacetylase activity, induced histone H3 acetylation, and an increased protein level of heat shock protein 70, which suggested disruption of heat shock protein 90 chaperone function for BCR-ABL and its degradation. Importantly, the combination of ponatinib with panobinostat showed synergistic growth inhibition and induced a higher level of apoptosis than the sum of the apoptosis induced by each agent alone in all of the cell lines. Ponatinib inhibited phosphorylation not only of BCR-ABL but also of downstream signal transducer and activator of transcription 5, protein kinase B, and ERK1/2 in both K562/IM-R1 and Ba/F3/T315I, and the addition of panobinostat to ponatinib further inhibited these phosphorylations. In conclusion, panobinostat enhanced the cytotoxicity of ponatinib towards IM-resistant CML cells including those with T315I-mutated BCR-ABL.
  • Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.
    Tamura Kazuo;Kawai Yasukazu;Kiguchi Toru;Okamoto Masataka;Kaneko Masahiko;Maemondo Makoto;Gemba Kenichi;Fujimaki Katsumichi;Kirito Keita;Goto Tetsuya;Fujisaki Tomoaki;Takeda Kenji;Nakajima Akihiro;Ueda Takanori
    International journal of clinical oncology 21(5) 996-1003 Mar.  2016
    BACKGROUND:Control of serum uric acid (sUA) levels is very important during chemotherapy in patients with malignant tumors, as the risks of tumor lysis syndrome (TLS) and renal events are increased with increasing levels of sUA. We investigated the efficacy and safety of febuxostat, a potent non-purine xanthine oxidase inhibitor, compared with allopurinol for prevention of hyperuricemia in patients with malignant tumors, including solid tumors, receiving chemotherapy in Japan.;METHODS:An allopurinol-controlled multicenter, open-label, randomized, parallel-group comparative study was carried out. Patients with malignant tumors receiving chemotherapy, who had an intermediate risk of TLS or a high risk of TLS and were not scheduled to be treated with rasburicase, were enrolled and then randomized to febuxostat (60ツꀀmg/day) or allopurinol (300 or 200ツꀀmg/day). All patients started to take the study drug 24ツꀀh before chemotherapy. The primary objective was to confirm the non-inferiority of febuxostat to allopurinol based on the area under the curve (AUC) of sUA for a 6-day treatment period.;RESULTS:Forty-nine and 51 patients took febuxostat and allopurinol, respectively. sUA decreased over time after initiation of study treatment. The least squares mean difference of the AUC of sUA between the treatment groups was -33.61ツꀀmgツꀀh/dL, and the 95ツꀀ% confidence interval was -70.67 to 3.45, demonstrating the non-inferiority of febuxostat to allopurinol. No differences were noted in safety outcomes between the treatment groups.;CONCLUSION:Febuxostat demonstrated an efficacy and safety similar to allopurinol in patients with malignant tumors receiving chemotherapy.;TRIAL REGISTRY:http://www.clinicaltrials.jp ; Identifier: JapicCTI-132398.
  • 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis
    Araie Hiroaki;Sakamaki Ippei;Matsuda Yasufumi;Tai Katsunori;Ikegaya Satoshi;Itoh Kazuhiro;Kishi Shinji;Oiwa Kana;Okura Miyuki;Tasaki Toshiki;Hosono Naoko;Ueda Takanori;Yamauchi Takahiro
    Internal Medicine 2017

    Objective We retrospectively compared the clinical efficacy and toxicity of rituximab (R)-THP-COP (pirarubicin, cyclophosphamide, vincristine, and prednisolone) with that of R-CHOP (rituximab, adriamicin, cyclophosphamide, vincristine, and prednisolone) in previously untreated old patients with diffuse large B-cell lymphoma (DLBCL).

    Patients and Methods Patients admitted to our institution between 2004 and 2013 were examined. The patients received either R (375 mg/m2, day 1) -THP-COP (pirarubicin 50 mg/m2 day 1, cyclophosphamide 750 mg/m2 day 1, vincristine 1.4 mg/m2 day 1, and prednisolone 100 mg day 1-5) or R-CHOP (adriamicin 50 mg/m2 day 1, cyclophosphamide 750 mg/m2 day 1, vincristine 1.4 mg/m2 day 1, and prednisolone 100 mg day 1-5). The doses of chemotherapeutic agents were adjusted depending on the patient's age and associated complications. The treatment was performed for 6 to 8 cycles.

    Results Among 74 patients with DLBCL (median 76, range 65-90 years; male 39, female 35), 29 received R-THP-COP, while 45 received R-CHOP. The overall response rates were 94.6% (complete response 86.4%, partial response 8.1%). The 2-year overall and progression-free survival rates were 77.6% and 68.5% for the R-THP-COP regimen and 79.2% and 78.9% for R-CHOP, respectively. No significant differences were found between these two regimens regarding the clinical efficacies. The most frequent adverse event was neutropenia (72.4% for the R-THP-COP regimen, 88.9% for the R-CHOP regimen). The cardiac function as evaluated by ejection fraction values was not impaired in either regimen.

    Conclusion R-THP-COP was effective and safe as an alternative to R-CHOP.

  • 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis.
    Araie Hiroaki;Sakamaki Ippei;Matsuda Yasufumi;Tai Katsunori;Ikegaya Satoshi;Itoh Kazuhiro;Kishi Shinji;Oiwa Kana;Okura Miyuki;Tasaki Toshiki;Hosono Naoko;Ueda Takanori;Yamauchi Takahiro
    Internal medicine (Tokyo, Japan) 2017
    :Objective We retrospectively compared the clinical efficacy and toxicity of rituximab (R)-THP-COP (pirarubicin, cyclophosphamide, vincristine, and prednisolone) with that of R-CHOP (rituximab, adriamicin, cyclophosphamide, vincristine, and prednisolone) in previously untreated old patients with diffuse large B-cell lymphoma (DLBCL). Patients and Methods Patients admitted to our institution between 2004 and 2013 were examined. The patients received either R (375 mg/m(2), day 1) -THP-COP (pirarubicin 50 mg/m(2) day 1, cyclophosphamide 750 mg/m(2) day 1, vincristine 1.4 mg/m(2) day 1, and prednisolone 100 mg day 1-5) or R-CHOP (adriamicin 50 mg/m(2) day 1, cyclophosphamide 750 mg/m(2) day 1, vincristine 1.4 mg/m(2) day 1, and prednisolone 100 mg day 1-5). The doses of chemotherapeutic agents were adjusted depending on the patient's age and associated complications. The treatment was performed for 6 to 8 cycles. Results Among 74 patients with DLBCL (median 76, range 65-90 years; male 39, female 35), 29 received R-THP-COP, while 45 received R-CHOP. The overall response rates were 94.6% (complete response 86.4%, partial response 8.1%). The 2-year overall and progression-free survival rates were 77.6% and 68.5% for the R-THP-COP regimen and 79.2% and 78.9% for R-CHOP, respectively. No significant differences were found between these two regimens regarding the clinical efficacies. The most frequent adverse event was neutropenia (72.4% for the R-THP-COP regimen, 88.9% for the R-CHOP regimen). The cardiac function as evaluated by ejection fraction values was not impaired in either regimen. Conclusion R-THP-COP was effective and safe as an alternative to R-CHOP.
  • Efficacy of aprepitant for CHOP chemotherapy-induced nausea, vomiting, and anorexia.
    Morita Mihoko;Kishi Shinji;Ookura Miyuki;Matsuda Yasufumi;Tai Katsunori;Yamauchi Takahiro;Ueda Takanori
    Current problems in cancer 2017
    :The objective of this study was to evaluate whether aprepitant in addition to 5-HT3 receptor antagonist is useful for preventing chemotherapy-induced nausea and vomiting (CINV) and anorexia in patients receiving CHOP therapy, and to evaluate the relationship between in vivo kinetics of plasma substance P and these adverse events. Patients with malignant lymphoma who received CHOP chemotherapy or THP (THP-ADR)-COP therapy were investigated for CINV and anorexia for 5 days after the start of chemotherapy. With the first course of chemotherapy, all patients received only granisetron on day1 as an antiemetic. Patients who experienced nausea, vomiting, or anorexia exceeding grade 1 in the first course received aprepitant for 3 days in addition to granisetron with the second course of CHOP chemotherapy. Plasma substance P concentrations at 24 and 72 hours after chemotherapy were measured. Nineteen patients were evaluated. Nausea, vomiting, or anorexia was observed with the first course in 7 of 19 patients. During the second course with aprepitant, no patients experienced vomiting, and the toxicity grade of nausea, vomiting, or anorexia was decreased compared with those in the first course. Substance P concentrations showed no differences after chemotherapy, in patients with nausea, vomiting, or anorexia and in patients without. The addition of aprepitant to 5-HT3 receptor antagonist appears effective for CINV or anorexia for patients who received CHOP chemotherapy.
  • YM155 exerts potent cytotoxic activity against quiescent (G0/G1) multiple myeloma and bortezomib resistant cells via inhibition of survivin and Mcl-1.
    Ookura Miyuki;Fujii Tatsuya;Yagi Hideki;Ogawa Takuya;Kishi Shinji;Hosono Naoko;Shigemi Hiroko;Yamauchi Takahiro;Ueda Takanori;Yoshida Akira
    Oncotarget 8(67) 2017
    :YM155, a novel small molecule inhibitor of survivin, shows broad anticancer activity. Here, we have focused on the cytotoxic activity of YM155 against multiple myeloma (MM) including cytokinetically quiescent (G0/G1) cells and bortezomib resistant cells. YM155 strongly inhibited the growth of MM cell lines with the IC50 value of below 10 nM. YM155 also showed potent anti-myeloma activity in mouse xenograft model. YM155 suppressed the expression of survivin and rapidly directed Mcl-1 protein for proteasome degradation. YM155 abrogated the interleukin-6-induced STAT3 phosphorylation, subsequently blocked Mcl-1 expression and induced apoptosis in MM cells. Triple-color flow cytometric analysis revealed that YM155 potently induced cell death of MM cells in G0 phase. Quiescent primary MM cells were also sensitive to YM155. We established bortezomib-resistant MM cell line, U266/BTZR1, which possess a point mutation G322A. YM155 exhibited similar cytotoxic potency against U266/BTZR1 compared with parental cells. Interestingly, survivin expression was markedly elevated in U266/BTZR1 cells. Treatment with YM155 significantly down-regulated this increased survivin and Mcl-1 expression in U266/BTZR1 cells. In conclusion, our data indicate that YM155 exhibits potent cytotoxicity against quiescent (G0/G1) MM cells and bortezomib-resistant cells. These unique features of YM155 may be beneficial for the development of new therapeutic strategies to eliminate quiescent MM cells and overcome bortezomib resistance.
  • [Evaluation of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematological Malignancies Using MASCC Antiemesis Tool(MAT)].
    Oiwa Kana;Hosono Naoko;Itoh Kazuhiro;Ookura Miyuki;Matsuda Yasufumi;Tai Katsunori;Ueda Takanori;Yamauchi Takahiro
    Gan to kagaku ryoho. Cancer & chemotherapy 45(1) 2018
    :Chemotherapy-induced nausea and vomiting(CINV)were prospectively evaluated using MASCC Antiemesis Tool(MAT) in patients with hematological malignancies in our institution. A total of 33 patients receiving 46 chemotherapy courses were evaluated. Although vomiting was not observed in the acute phase, nausea was seen in 22.6% and 32.3% of the patients in the acute and delayed phases, respectively. Thirty percent(25 cases)of the patients receiving highly emetogenic chemotherapy presented nausea in both the phases, while 40%(18 cases)of the patients receiving moderately emetogenic chemotherapy presented nausea in the delayed phase. The oral intake was quantitated retrospectively in 31 patients with non- Hodgkin's lymphoma, who were hospitalized and received CHOP±R. Prior to the initiation of the chemotherapy, 13 patients received the first generation 5-HT3 receptor antagonist granisetron, while 18 patients received the second generation palonosetron. Oral intake was greater in the patients who were administered palonosetron. Thus, the present study suggested that antiemetic treatment could be improved at our institution.
  • 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis
    Araie Hiroaki;Sakamaki Ippei;Matsuda Yasufumi;Tai Katsunori;Ikegaya Satoshi;Itoh Kazuhiro;Kishi Shinji;Oiwa Kana;Okura Miyuki;Tasaki Toshiki;Hosono Naoko;Ueda Takanori;Yamauchi Takahiro
    Internal Medicine 56(18) 2407-2413 2017

    Objective We retrospectively compared the clinical efficacy and toxicity of rituximab (R)-THP-COP (pirarubicin, cyclophosphamide, vincristine, and prednisolone) with that of R-CHOP (rituximab, adriamicin, cyclophosphamide, vincristine, and prednisolone) in previously untreated old patients with diffuse large B-cell lymphoma (DLBCL).

    Patients and Methods Patients admitted to our institution between 2004 and 2013 were examined. The patients received either R (375 mg/m2, day 1)-THP-COP (pirarubicin 50 mg/m2 day 1, cyclophosphamide 750 mg/m2 day 1, vincristine 1.4 mg/m2 day 1, and prednisolone 100 mg day 1-5) or R-CHOP (adriamicin 50 mg/m2 day 1, cyclophosphamide 750 mg/m2 day 1, vincristine 1.4 mg/m2 day 1, and prednisolone 100 mg day 1-5). The doses of chemotherapeutic agents were adjusted depending on the patient's age and associated complications. The treatment was performed for 6 to 8 cycles.

    Results Among 74 patients with DLBCL (median 76, range 65-90 years; male 39, female 35), 29 received R-THP-COP, while 45 received R-CHOP. The overall response rates were 94.6% (complete response 86.4%, partial response 8.1%). The 2-year overall and progression-free survival rates were 77.6% and 68.5% for the R-THP-COP regimen and 79.2% and 78.9% for R-CHOP, respectively. No significant differences were found between these two regimens regarding the clinical efficacies. The most frequent adverse event was neutropenia (72.4% for the R-THP-COP regimen, 88.9% for the R-CHOP regimen). The cardiac function as evaluated by ejection fraction values was not impaired in either regimen.

    Conclusion R-THP-COP was effective and safe as an alternative to R-CHOP.

Books etc

  • Chemotherapy for Leukemia Novel Drugs and Treatment
    Takanori Ueda
    Springer Singapore Apr.  2017
    978-981-10-3330-8
  • Enhancement of the Effects of Antineoplastic Agents Based on their Action Mechanism.
    T.Ueda
     1987
  • A pharmacokinetic study 1-β-D-arabinofuranosylcytosine-5'-stearylphosphate(steary1-ara-CMP)in patients with hematologic malignancies.
    T.Ueda
     1990
  • Study on atypical lymphocytes in rickettsial infections in Japan.
    T.Ueda
     1990
  • Purine nucleotide biosynthesis in leukemic promyelocytes treated with retinoids.
    T.Ueda
     1991
  • Detection of Candida antigen and D-arabinitol for diagnosing Candida infection in sera of patients with hematological diseases.
    T.Ueda
     1991
  • Mixed leukemia(共著)
    T.Ueda
     1992
  • Daunorubicin resistance in a K562-derived cell line and its reversal by Idarubicin. The Mechanism and New Approach on Drug Resistance of Cancer Cells(Miyazaki. T. , Takaku. F. , Sakurada. K. )
    T.Ueda
     1993
  • A new diagnostic aid for deep mycosis associated with hematologic disease using (1→3) - β -D- glucan assay. (共著)
    T.Ueda
     1994
  • Mechanism of action of SM5887, a new anthracvcline agent, in HL60 cells. (共著)
    T.Ueda
     1994
  • Different doses of cytosine arabinoside in leukemia chemotherapy have different mechanisms of action. (共著)
    T.Ueda
     1994
  • Mechanism of multidrug resistance in daunorubicin resistant K562 cell line.
    T.Ueda
     1995
  • Very low dose etoposide treatment for the aged patients with malignant lymphoma.
    T.Ueda
     1997
  • Acute leukemia
    T.Ueda
     1997
  • Serial change of myocardial fatty acid utilization after revascularization-correlation between myocardial stunning and hibernating
    T.Ueda
     1997
  • Acute lymphoblastic leukemia
    T.Ueda
     1998
  • The ALL90 study : Response-oriented individualized induction therapy followed by intensive consolidation, maintenance and intensification therapy.
    T.Ueda
     1999
  • Regional Reduction in Myocardial Glucose Utilization Predicts Cardiac Events in Dilated Cardiomyopathy. Positron Emission Tomography in the Millennium
    T.Ueda
     2000
  • Serial Changes in Glucose and Free Fatty Acid Utilization in Reperfused Myocardium
    T.Ueda
     2000